Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

Luca Gianni(Fondazione Michelangelo), Giuseppe Viale(University of Milan), Milvia Zambetti(Hospital Clínico Universitario de Valencia), Giancarlo Bisagni, Marco Colleoni(European Institute of Oncology), Pinuccia Valagussa(Fondazione Michelangelo), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Lucia Del Mastro(Ospedale Policlinico San Martino), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Raffaella De Fato(Fondazione Michelangelo), Mauro Mansutti(Ospedale Santa Maria della Misericordia di Udine)
The Lancet Oncology
January 8, 2018
10.1016/s1470-2045(18)30001-9
Cited by 174

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k